uniQure prices IPO at $17, above the range

By Renaissance Capital,

Shutterstock photo

uniQure, a biotech developing gene therapies for the treatment of orphan diseases, raised $92 million by offering 5.4 million shares at $17, above the range of $13-$15. uniQure plans to list on the NASDAQ under the symbol QURE. Jefferies and Leerink Partners acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: QURE

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com